immuno-oncology

News
MSD hits a hurdle with its LAG-3 programme

MSD hits a hurdle with its LAG-3 programme

MSD's combination of PD-1 inhibitor Keytruda and experimental LAG-3 inhibitor favezelimab has failed a phase 3 trial in patients with previously treated PD-L1-positive microsatellite stable

News
A 3D bioprinter creates small, three-dimensional tumours in a collagen gel that continue to grow. The researchers then add T-cells and observe what happens.

3D-printed tumours could aid cancer therapy R&D

Researchers in the Netherlands have developed 3D-printed 'mini tumours' that behave like real cancerous tissue and can be used to test new treatments, including drug and cell-based immunoth